The use of granulocytic colony-stimulating factors in patients receiving chemotherapy for germ cell tumors
Germ cell tumors (GCT) are a relatively rare malignancy occurring in adolescent/young males in the vast majority of cases. With the advent of platinum containing regimens 4 decades ago, impressive cure rates have been achieved both in the adjuvant setting and in first line for advanced disease, with the vast majority of patients being cured. Moreover, 35 to 50% of patients with recurrent disease can be cured with conventional orhigh-dose chemotherapy programs.
Neutropenia and its complications (mainly neutropenic fever) may be a limiting toxicity with the
risk of reducing the planned curative doses or delaying intervals with potential impact on outcome. Granulocytic-hematopoietic growth factors (G-CSFs) by limiting neutropenia and neutropenic fever allow the delivery of curative chemotherapy in a safer manner to GCTs patients. We will present an overview of the use of G-CSF in this setting.